<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00244829</url>
  </required_header>
  <id_info>
    <org_study_id>1867.00</org_study_id>
    <secondary_id>FHCRC-1867.00</secondary_id>
    <secondary_id>CDR0000355118</secondary_id>
    <nct_id>NCT00244829</nct_id>
  </id_info>
  <brief_title>Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia</brief_title>
  <official_title>A Multicenter Pilot Study Evaluating the Safety and Efficacy of Imatinib as Post-Transplant Therapy for High- Risk Philadelphia Chromosome-Positive Leukemias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the&#xD;
      enzymes needed for cell growth. Giving imatinib mesylate after a donor stem cell transplant&#xD;
      may prevent the recurrence of Philadelphia chromosome-positive leukemia.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects of giving imatinib mesylate after&#xD;
      a donor stem cell transplant and to see how well it works in treating patients with&#xD;
      Philadelphia chromosome-positive leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety of adjuvant imatinib mesylate after allogeneic hematopoietic stem&#xD;
           cell transplantation (AHSCT) in patients with high-risk Philadelphia chromosome-positive&#xD;
           leukemia.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the bcr/abl transcript load during the first 90 days after AHSCT in patients&#xD;
           treated with this drug from the time of engraftment.&#xD;
&#xD;
        -  Determine the 1-year survival of patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is an open-label, pilot, multicenter study.&#xD;
&#xD;
      Beginning within 14-30 days after allogeneic stem cell transplantation, patients receive oral&#xD;
      imatinib mesylate once daily until 1 year after transplantation. Treatment continues in the&#xD;
      absence of unacceptable toxicity or disease progression.&#xD;
&#xD;
      Patients are followed for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety at 90 days following transplant</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>BCR/ABL transcript load at 90 days following transplant</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard management of progressive minimal residual disease at 90 days following transplant</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival at 1 year</measure>
  </secondary_outcome>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following:&#xD;
&#xD;
               -  Acute lymphoblastic leukemia or chronic myeloid leukemia (CML) characterized by&#xD;
                  p^190 and/or p^210 bcr/abl gene rearrangement&#xD;
&#xD;
               -  Accelerated or blastic phase CML&#xD;
&#xD;
               -  CML in second or greater chronic phase&#xD;
&#xD;
          -  No imatinib mesylate-resistant leukemia&#xD;
&#xD;
          -  Planned allogeneic hematopoietic stem cell transplantation&#xD;
&#xD;
               -  Availability of an appropriately matched related or unrelated donor&#xD;
&#xD;
               -  Autologous or nonmyeloablative transplantation is not allowed&#xD;
&#xD;
          -  None of the following within 4 days after the date of neutrophil engraftment*:&#xD;
&#xD;
               -  More than 5% marrow blasts&#xD;
&#xD;
               -  Circulating peripheral blood leukemic blasts&#xD;
&#xD;
               -  Aberrant antigen expression on marrow myeloblasts ≥ 1% by multidimensional flow&#xD;
                  cytometric assay&#xD;
&#xD;
               -  Presence of bcr/abl in &gt; 5% of marrow interphase nuclei by fluorescent in situ&#xD;
                  hybridization&#xD;
&#xD;
               -  More than 1 of 20 Philadelphia chromosome-positive marrow metaphases&#xD;
&#xD;
               -  CNS involvement by leukemia NOTE: *The date of neutrophil engraftment is defined&#xD;
                  as the second consecutive day at which the peripheral blood absolute neutrophil&#xD;
                  count exceeds 500/mm3&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 2 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,200/mm^3 (use of filgrastim [G-CSF] allowed)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No known imatinib mesylate hypersensitivity&#xD;
&#xD;
          -  No other disease that severely limits life expectancy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Carpenter, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>October 25, 2005</study_first_submitted>
  <study_first_submitted_qc>October 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2005</study_first_posted>
  <last_update_submitted>November 28, 2011</last_update_submitted>
  <last_update_submitted_qc>November 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2011</last_update_posted>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

